Session 18 - CROI 2009

Session 18 Oral Abstracts
Mechanisms of Drug Resistance and Optimal Timing of ART
Monday, 4-6:15 pm
Room: Room 517b-d

4:00 pm 65LB	Potent HIV-1 PI Resilient to Resistance Developed Using the Substrate Envelope Hypothesis M Nalam¹, A Ali¹, G Reddy¹, M Altman², S Chellappan³, S Anjum¹, T Rana⁴, M Gilson³, B Tidor², and Celia Schiffer*¹ ¹Univ of Massachusetts Med Sch, Worcester, US; ²Massachusetts Inst of Tech, Cambridge, US; ³Ctr for Advanced Res in Biotech, Univ of Maryland, Rockville, US; and ⁴Burham Inst for Med Res, La Jolla, CA, US
4:15 pm 66LB	High-resolution Crystallographic Analysis of the Competitive Binding of a Novel Nucleotide Analog GS-9148-Diphosphate to HIV-1 Reverse Transcriptase Eric Lansdon*, D Samuel, L Lagpacan, K White, C Boojamra, R Mackman, T Cihlar, A Ray, M McGrath, and S Swaminathan Gilead Sci, Foster City, CA, US
4:30 pm 67	Structural Basis for HIV-1 Reverse Transcriptase Drug Resistance to Zidovudine and Tenofovir Kalyan Das*¹, X Tu¹, R Bandwar¹, S Sarafianos¹, S Tuske¹, P Boyer², K White³, M Miller³, S Hughes², and E Arnold¹ ¹Ctr for Advanced Biotech and Med, Rutgers Univ, Piscataway, NJ, US; ²HIV Drug Resistance Prgm, NCI, Frederick, MD, US; and ³Gilead Sci, Foster City, CA, US
4:45 pm 68	N348I in HIV-1 Reverse Transcriptase Counteracts the Antagonism between Thymidine Analogue Mutations and Y181C Jessica Radzio*^1,2, S-H Yapp³, R Harrigan⁴, G Tachedjian³, and N Sluis-Cremer² ¹Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US; ²Univ of Pittsburgh Sch of Med, PA, US; ³Macfarlane Burnet Inst, Melbourne, Australia and Monash Univ, Churchill, Australia; and ⁴BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada
5:00 pm 69	HIV-1 Mutations at Positions 143, 148, and 155 of Integrase Define Different Genetic Barriers to Raltegravir Resistance in vivo Signe Fransen*, S Gupta, A Frantzell, C Petropoulos, and W Huang Monogram Biosci, South San Francisco, CA, US
5:15 pm 70aLB	Switching from Stable Lopinavir/Ritonavir-based to Raltegravir-based Combination ART Resulted in a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 Joseph Eron*¹, J Andrade², R Zajdenverg³, C Workman⁴, D Cooper⁵, B Young⁶, X Xu⁷, B-Y Nguyen⁷, R Leavitt⁷, and P Sklar⁷ ¹Univ of North Carolina at Chapel Hill, US; ²Antinguo Hosp Civil de Guadalajara, Mexico; ³Hosp Escola Sao Francisco de Assis, Rio de Janeiro, Brazil; ⁴AIDS Res Initiative, Darlinghurst, Australia; ⁵Univ of New South Wales, Sydney, Australia; ⁶Denver Infectious Disease Consultants, CO, US; and ⁷Merck Res Labs, West Point, PA, US
5:30 pm 70bLB	Transient HAART during PHI Prolongs the Total Time off HAART in Patients Presenting with PHI: Data from the Dutch Primo SHM Cohort Radjin Steingrover*¹, S Jurriaans¹, M Grijsen¹, F de Wolf², J Lange¹, J Prins¹, and the Primo-SHM Study Group ¹Academic Med Ctr, Amsterdam, The Netherlands and ²HIV Monitoring Fndn, Amsterdam, The Netherlands
5:45 pm 71	Initiating rather than Deferring HAART at a CD4⁺ Count >500 Cells/mm³ Is Associated with Improved Survival Mari Kitahata*¹, S Gange², R Moore², and the North American AIDS Cohort Collaboration on Res and Design ¹Univ of Washington, Seattle, US and ²Johns Hopkins Univ, Baltimore, MD, US
6:00 pm 72LB	When Should HIV-1-infected Persons Initiate ART? Collaborative Analysis of HIV Cohort Studies Jonathan Sterne and the When To Start Consortium Univ of Bristol, UK